First of its Kind Self-Referential Narrative "The Patent '813 Story, Part II, Version 2" Calls on The New York Times and Wall Street Journal to Investigate Law360 for its Role in Reporting on the Story

WILMINGTON, Del., Jan. 16, 2016 /PRNewswire/ -- Lucerne Biosciences, LLC announced today that it is providing logistical communications support for what has become a unique "first of its kind self-referential narrative" called "The Patent '813 Story, Part II, Version 2" that has been designed to resolve itself through "the truth of the matter."  "The Patent '813 Story, Part II, Version 2" utilizes "recursive, non-projective communication" to drive a group dynamic that allows the behavior of its main "real life characters," mainly attorneys, to converge on its own "narrative self" to drive its final resolution.  Lucerne Biosciences' Manager Louis Sanfilippo, MD, also a psychiatrist, stated, "The self-referential narrative has come to a point that any reasonable person reading it would see that it is loudly calling on The New York Times and Wall Street Journal, particularly journalists Steve Lohr and Ed Silverman respectively, to support an investigation of Law360 for how it has handled its 'legal reporting role' in the story. And that opens up another dimension of the story, namely, how the legal community has handled its own role in the story across its many layers.  It's hard to believe.   Which is why the story is also loudly inviting the public-at-large to join the investigation by first taking a look at the story itself and evidence it produces, perhaps beginning with its last entry or two so you're immediately up-to-speed in real-time, ready to see what happens next."

The Patent '813 Story, Part II, Version 2" derives from an Inter Partes Review initiated by Shire Development LLC on May 9, 2014 against LCS Group, LLC, a small Connecticut company that at the time was the owner of U.S. Patent 8,318,813 titled Method of Treating Binge Eating Disorder and whose claims encompassed an indication for which Shire had received FDA approval on January 30, 2015.   Lucerne Biosciences, LLC acquired full ownership of the patent in January 2015 while giving LCS Group, LLC exclusive rights to commercialize the patent according to the terms of a license between the two companies.  The '813 Patent was invalidated on June 4, 2015 by the Patent Trial & Appeal Board. 

Lucerne Biosciences' Manager Sanfilippo also stated, "the communications systems methodology for this self-referential narrative was designed to establish a frame of reference by which representations and behavior could be chronicled in real-time for any reasonable person to read and understand for its implications.  It's essentially a deception detection method and has involved close collaboration between parties once the communication protocol was established, which effectively took place on October 1, 2014, shortly after Shire ignored a series of communications LCS Group made to inform the company it had a problem it ought to deal with sooner than later. The beauty of the story is that it's all there and speaks for itself, available for the public-at-large to investigate first hand for its own interest.  And there are plenty of surprises, most recently being how the story is apparently making its own transition to a yet-to-be announced Internet platform in the public interest as it calls on The NY Times and Wall Street Journal to give some attention to Law360, as well as to itself and its other narrative features.  This comes on the heels of the company completing a 'sourcing investigation' of Shire's IPR behavior on January 11, 2016.  The bottom line now is that there isn't any more room for concealment. That means the story has reached a point of speaking about itself through its real-life characters in a 'final resolution,' whom you can find on page 785 of the latest PDF version of the narrative, updated in real-time."  

Additional, Related Information

The Patent '813 Story, Part II, Version 2 (updated January 16, 2016 at 7:20 AM EST) at: https://app.box.com/s/kbpjbsxwl8f9cb3loprj9n071lzn87af

Lucerne Biosciences Completes Sourcing Investigation into Shire's IPR that Led to the Invalidation of the '813 Patent; Begins Accelerated Multi-Party Public Expansion Phase of its Counter-Intelligence Technology  (January 15, 2016) at: http://www.prnewswire.com/news-releases/lucerne-biosciences-completes-sourcing-investigation-into-shires-ipr-that-led-to-the-invalidation-of-the-813-patent-300205005.html  or in PDF at: https://app.box.com/s/p45yq0h0gun3scx9b8f10uxcoh7vg5q4

LCS Group Accelerates Commercialization Plan of its Exclusively Licensed '813 Patent to Treat Binge Eating Disorder with Lisdexamfetamine Dimesylate Using '813 Patent Owner's "Deception Detection Technology," Now Freely Available Online to the Global Public-at-large (January 15, 2016) at: http://www.prnewswire.com/news-releases/lcs-group-accelerates-commercialization-plan-of-its-exclusively-licensed-813-patent-to-treat-binge-eating-disorder-with-lisdexamfetamine-dimesylate-using-813-patent-owners-deception-detection-technology-now-freely-available--300205009.html  or in PDF at: https://app.box.com/s/rhdcafckys0u6tffd7vhnkj30g8k7in3

LCS Group Accelerates Commercialization of its Exclusively Licensed '813 Patent to Treat Binge Eating Disorder with Lisdexamfetamine Dimesylate Using the '813 Patent Owner's "Deception Detection Technology," Now Freely Available Online to the Global Public-at-large (January 13, 2016) at: http://www.prnewswire.com/news-releases/lcs-group-accelerates-commercialization-plan-of-its-exclusively-licensed-813-patent-to-treat-binge-eating-disorder-with-lisdexamfetamine-dimesylate-using-813-patent-owners-deception-detection-technology-now-freely-available--300204246.html

Lucerne Biosciences Completes Sourcing Investigation into Shire's IPR that Led to the Invalidation of the '813 Patent; Begins Accelerated Multi-Party Public Expansion Phase of its Counter-Intelligence Technology (January 11, 2016) at: http://www.prnewswire.com/news-releases/lucerne-biosciences-completes-sourcing-investigation-into-shires-ipr-that-led-to-the-invalidation-of-the-813-patent-begins-accelerated-multi-party-public-expansion-phase-of-its-counter-intelligence-technology-300202785.html

PTAB Invalidates Lucerne Biosciences' '813 Patent for the Treatment of Binge Eating Disorder with Lisdexamfetamine Dimesylate (June 13, 2015) at: http://www.prnewswire.com/news-releases/ptab-invalidates-lucerne-biosciences-813-patent-for-the-treatment-of-binge-eating-disorder-with-lisdexamfetamine-dimesylate-300098752.html

LCS Group Announces Exclusive License from Lucerne Biosciences to Commercialize '813 Patent and '249 Application through Shire's Marketing of Lisdexamfetamine Dimesylate for Binge Eating Disorder (May 13, 2015) at: http://www.prnewswire.com/news-releases/lcs-group-announces-exclusive-license-from-lucerne-biosciences-to-commercialize-813-patent-and-249-application-through-shires-marketing-of-lisdexamfetamine-dimesylate-for-binge-eating-disorder-300083124.html

Lucerne Biosciences Announces Publication of Claimed Methods for Treating Binge Eating Disorder with Lisdexamfetamine Dimesylate (March 6, 2015) at: http://www.prnewswire.com/news-releases/lucerne-biosciences-announces-publication-of-claimed-methods-for-treating-binge-eating-disorder-with-lisdexamfetamine-dimesylate-300046271.html

LCS Therapeutics and Lucerne Biosciences to Commercialize '813 Patent for Lisdexamfetamine Dimesylate in the Treatment of Binge Eating Disorder (December 26, 2014) at: http://www.prnewswire.com/news-releases/lcs-therapeutics-and-lucerne-biosciences-to-commercialize-813-patent-for-lisdexamfetamine-dimesylate-in-the-treatment-of-binge-eating-disorder-300013986.html

Media Contact:

Louis Sanfilippo, MD
203-521-1143

Communications can be made to [email protected].

SOURCE Lucerne Biosciences, LLC